Similar articles for PMID: 36696828

Year	Number of Results
2007	2
2008	4
2009	4
2010	6
2011	7
2012	9
2013	10
2014	16
2015	10
2016	7
2017	10
2018	7
2019	6
2020	5
2021	8
2022	7
2023	8
2024	0

1

Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.

Mohammadi F, Rostami G, Hamid M, Shafiei M, Azizi M, Bahmani H. Mohammadi F, et al. Leuk Res. 2023 Mar;126:107021. doi: 10.1016/j.leukres.2023.107021. Epub 2023 Jan 21. Leuk Res. 2023. PMID: 36696828

2

Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.

Mohammadi F, Shafiei M, Assad D, Rostami G, Hamid M, Foroughmand AM. Mohammadi F, et al. Iran Biomed J. 2021 Jan;25(1):54-61. doi: 10.29252/ibj.25.1.54. Epub 2020 Aug 25. Iran Biomed J. 2021. PMID: 33129240 Free PMC article.

3

Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.

Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, Ankathil R. Au A, et al. Biomed Pharmacother. 2014 Apr;68(3):343-9. doi: 10.1016/j.biopha.2014.01.009. Epub 2014 Feb 7. Biomed Pharmacother. 2014. PMID: 24581936 Clinical Trial.

4

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis.

Dalle Fratte C, Polesel J, Gagno S, Posocco B, De Mattia E, Roncato R, Orleni M, Puglisi F, Guardascione M, Buonadonna A, Toffoli G, Cecchin E. Dalle Fratte C, et al. Int J Mol Sci. 2023 Feb 7;24(4):3303. doi: 10.3390/ijms24043303. Int J Mol Sci. 2023. PMID: 36834713 Free PMC article.

5

Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.

Jiang ZP, Zhao XL, Takahashi N, Angelini S, Dubashi B, Sun L, Xu P. Jiang ZP, et al. Pharmacogenomics. 2017 Jan;18(1):35-56. doi: 10.2217/pgs-2016-0103. Epub 2016 Dec 19. Pharmacogenomics. 2017. PMID: 27991849

6

Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.

Mohammadi F, Rostami G, Assad D, Shafiei M, Hamid M, Jalaeikhoo H. Mohammadi F, et al. Lab Med. 2021 Nov 2;52(6):584-596. doi: 10.1093/labmed/lmab023. Lab Med. 2021. PMID: 34128532

7

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.

Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR. Seong SJ, et al. Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31. Ann Oncol. 2013. PMID: 23117072 Free article.

8

Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.

Salimizand H, Amini S, Abdi M, Ghaderi B, Azadi NA. Salimizand H, et al. Tumour Biol. 2016 Jan;37(1):791-8. doi: 10.1007/s13277-015-3874-4. Epub 2015 Aug 7. Tumour Biol. 2016. PMID: 26250462

9

Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.

Adeagbo BA, Bolaji OO, Olugbade TA, Durosinmi MA, Bolarinwa RA, Masimirembwa C. Adeagbo BA, et al. J Clin Pharm Ther. 2016 Oct;41(5):546-51. doi: 10.1111/jcpt.12424. Epub 2016 Jul 18. J Clin Pharm Ther. 2016. PMID: 27426203

10

A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.

Francis J, Dubashi B, Sundaram R, Pradhan SC, Chandrasekaran A. Francis J, et al. Cancer Chemother Pharmacol. 2015 Dec;76(6):1185-9. doi: 10.1007/s00280-015-2905-6. Epub 2015 Nov 6. Cancer Chemother Pharmacol. 2015. PMID: 26546461

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

103 results

Results by year